PHILADELPHIA -- GlaxoSmithKline (GSK) announced the launch of a pivotal trial with its investigational influenza vaccine, Fluarix, in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. National Institutes of Health (NIH), part of the Department of Health and Human Services.
The phase III trial will start this month and will be conducted at four centers in the United States, including the University of Rochester Medical Center, the University of Maryland School of Medicine, Baltimore, Cincinnati Children's Hospital and Baylor College of Medicine.
The randomized, double-blind placebo-controlled trial will involve approximately 1,000 participants 18 to 64 years of age. The objective of the trial is to evaluate the immunogenicity and safety of Fluarix administered intramuscularly in healthy adults.
Four out of every five participants in this trial will receive Fluarix, while the fifth will receive a placebo. Those receiving placebo will be offered flu vaccine at the conclusion of the month-long study.
GSK has not filed a biologics license application (BLA) for Fluarix in the United States, however, as a result of this year's flu vaccine shortage, Fluarix is now available for use in the United States under the Investigational New Drug regulations. Results of this pivotal trial will be provided to FDA as GSK seeks licensure for Fluarix under biologics license application (BLA) in 2005.
Fluarix is a trivalent inactivated virus vaccine manufactured in a GSK facility in Germany. Each 0.5 ml dose of Fluarix contains 15 micrograms of highly purified sub-units of each of the three influenza virus strains. The vaccine contains trace levels of egg protein and should not be used by individuals with egg or chicken protein allergies.
Source: GlaxoSmithKline
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.